Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM
Annamaria Brioli(Universitätsmedizin Greifswald), Michèle Cavo(Unknown), Mario Boccadoro(University of Turin), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Annalisa Pezzi, Francesco Nobile(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Felicetto Ferrara(San Antonio College), Serena Rocchi(University of Bologna), Pellegrino Musto(University of Bari Aldo Moro), Katia Mancuso(Istituto di Ematologia di Bologna), Letizia Canepa(Fondazione Gimema Onlus), Antonio Lazzaro(Guglielmo da Saliceto Hospital), Lucio Catalano(University of Naples Federico II), Daniele Derudas(Centro di Riferimento Oncologico), Anna Baraldi(Fondazione Gimema Onlus), Beatrice Anna Zannetti(University of Bologna), Graziella Pinotti(Medica (Italy)), Maria Concetta Petti(Fondazione Gimema Onlus)
Cited by 3
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k